2025-10-29 01:16:45
Latest Post
3i Infotech Limited allots 3,77,08,165 equity shares on rights basis, Issue oversubscribed 1.45 times
Reliance Power Ltd appoints retired IAS Officer Ms. Zohra Chatterji as Independent Director
Airfloa Rail Technology Ltd receives order worth Rs. 23.91 crores
Macfos Ltd consolidated Q2FY26 net profit up QoQ at Rs. 5.10 crore
Jasch Gauging Technologies Ltd Q2 FY2025-26 net profit at Rs. 5.13 crore
Stock Report
Jenburkt Pharmaceuticals Ltd Q2 FY2025-26 PAT up at Rs. 10.16 crores
Posted On : 2025-10-28 19:06:54( TIMEZONE : IST )
JENBURKT PHARMACEUTICALS LTD. has reported Standalone financial results for the period ended September 30, 2025.
Financial Results (Q2 FY2026) - QoQ Comparison
The company has reported total income of Rs. 47.6366 crores during the period ended September 30, 2025 as compared to Rs. 37.5839 crores during the period ended June 30, 2025.
The company has posted net profit / (loss) of Rs. 10.1634 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs. 7.7918 crores for the period ended June 30, 2025.
The company has reported EPS of Rs. 23.03 for the period ended September 30, 2025 as compared to Rs. 17.66 for the period ended June 30, 2025.
| Financials | Q2 FY2026 | Q1 FY2026 | % Change |
| Total Income | ₹ 47.6366 crs | ₹37.5839 crs |  26.75% |
| Net Profit | ₹10.1634 crs | ₹7.7918 crs | 30.44% |
| EPS | ₹23.03 | ₹17.66 | 30.41% |
Financial Results (Q2 FY2026) - YoY Comparison
The company has reported total income of Rs. 47.6366 crores during the period ended September 30, 2025 as compared to Rs.43.0692 crores during the period ended September 30, 2024.
The company has posted net profit / (loss) of Rs.10.1634 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs.9.6005 crores for the period ended September 30, 2024.
The company has reported EPS of Rs.23.03 for the period ended September 30, 2025 as compared to Rs.21.75 for the period ended September 30, 2024.
| Financials | Q2 FY2026 | Q2 FY2025 | % Change |
| Total Income | ₹ 47.6366 crs | ₹43.0692 crs | 10.60% |
| Net Profit | ₹10.1634 crs | ₹9.6005 crs | 5.86% |
| EPS | ₹23.03 | ₹21.75 | 5.89% |
Financial Results (Half Year Ended FY2026) - YoY Comparison
The company has reported total income of Rs.85.2205 crores during the 6 Months period ended September 30, 2025 as compared to Rs.77.0106 crores during the 6 Months period ended September 30, 2024.
The company has posted net profit / (loss) of Rs.17.9552 crores for the 6 Months period ended September 30, 2025 as against net profit / (loss) of Rs.17.0165 crores for the 6 Months period ended September 30, 2024.
The company has reported EPS of Rs.40.68 for the 6 Months period ended September 30, 2025 as compared to Rs.38.56 for the 6 Months period ended September 30, 2024.
| Financials | Half Year Ended FY2026 | Half Year Ended FY2025 | % Change |
| Total Income | ₹85.2205 crs | ₹77.0106 crs | 10.66% |
| Net Profit | ₹17.9552 crs | ₹17.0165 crs | 5.52% |
| EPS | ₹40.68 | ₹38.56 | 5.50% |
Shares of JENBURKT PHARMACEUTICALS LTD. was last trading in BSE at Rs. 1089.20 as compared to the previous close of Rs. 1070.20. The total number of shares traded during the day was 1436 in over 116 trades.
The stock hit an intraday high of Rs. 1110.00 and intraday low of 1051.00. The net turnover during the day was Rs. 1543903.00.
